EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and ...
Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific ...
Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term ...
Imviva Biotech maintains ongoing collaboration with the FDA, as demonstrated by the February 2025 IND clearance and January 2026 orphan drug designation for CD7-targeted therapy CTD402 in T-cell ...
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options. The introduction of CD19 ...
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report The ...
New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple ...
B-cell depletion with unconjugated CD20 monoclonal antibody (mAb) is used to treat rheumatoid arthritis and other autoimmune diseases. CD20-targeted immunotherapy depletes mature B cells through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results